During the past decade, Tokyo Metropolitan Children's Medical Center conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 5 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tokyo Metropolitan Children's Medical Center" #1 sponsor was "Pfizer" with 3 trials, followed by "Bayer" with 2 trials sponsored, "Reata Pharmaceuticals, Inc." with 2 trials sponsored, "Eli Lilly and Company" with 1 trials sponsored and "Jerry Zimmerman" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Metropolitan Children's Medical Center" #1 collaborator was "Regeneron Pharmaceuticals" with 2 trials as a collaborator, "Canadian Critical Care Trials Group" with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator, "Children's Hospital of Eastern Ontario" with 1 trials as a collaborator and "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Tokyo Metropolitan Children's Medical Center" are "Alport Syndrome" (2 trials), "Hypertension, Pulmonary" (2 trials), "Retinopathy of Prematurity (ROP)" (2 trials), "Apnea of Prematurity" (1 trials) and "Autosomal Dominant Polycystic Kidney" (1 trials). Many other conditions were trialed in "Tokyo Metropolitan Children's Medical Center" in a lesser frequency.

Most popular intervention types in "Tokyo Metropolitan Children's Medical Center" are "Drug" (13 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Eylea (Aflibercept, BAY86-5321)" (2 trials), "Laser photocoagulation" (2 trials), "Bardoxolone Methyl" (1 trials), "Bardoxolone methyl" (1 trials) and "Dexmedetomidine hydrochloride" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tokyo Metropolitan Children's Medical Center" are 12 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Tokyo Metropolitan Children's Medical Center". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Tokyo Metropolitan Children's Medical Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Tokyo Metropolitan Children's Medical Center, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Tokyo Metropolitan Children's Medical Center has several departments that took part in Clinical trials: "Tokyo Metropolitan Neurological Hospital" - 5 trials